Trial Search Results

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

The purpose of this study is find out whether an investigational (experimental) drug called CPI-444 can be used, either on its own, or in combination with another investigational drug called atezolizumab (also known as MPDL3280A) on you and the specific type of cancer you have.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator: Genentech, Inc.


  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444
  • Drug: CPI-444 + atezolizumab
  • Drug: CPI-444


Phase 1


Inclusion Criteria

   1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

   2. Documented incurable cancer with one of the following histologies: non-small cell lung
   cancer, malignant melanoma, renal cell cancer, triple negative breast cancer,
   colorectal cancer with microsatellite instability (MSI), bladder cancer, and
   metastatic castration resistant prostate cancer.

   3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST

   4. At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or
   progressing disease.

Exclusion Criteria

   1. History of severe hypersensitivity reaction to monoclonal antibodies.

   2. Any active autoimmune disease or a documented history of serious autoimmune disease
   within the past 5 years requiring immunosuppressive therapy.

   3. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
   pneumonitis, idiopathic pneumonitis, or clinical symptoms of active pneumonitis.

   4. The use of any investigational medication or device in the 30 days prior to screening
   and throughout the study is prohibited.

   5. If a patient is currently receiving denosumab, this must be discontinued prior to
   enrollment. Substitution with biphosphonates are acceptable.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Nimna Ranatunga